VCP Scanner
ScreenerTechnicalBreakoutsThemes
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
VisualizeInteractive multi-year financial charts
Earnings
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Pharma & Energy
LLY vs NVOJNJ vs PFEXOM vs CVX
Compare Any Stocks...
WatchlistPricing
ScreenerTechnical ScannerBreakoutsThemes
Earnings
WatchlistPricing
Ctrl K
ELAN
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Analyze deeply. Research with clarity.

Data updated daily

Product

  • Screener
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • Pricing
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly market insights — free

© 2026 VCP Scanner
AboutPrivacyTermsRefund Policy
Not financial advice. Do your own research.
ScreenerBreakoutsCompareWatchlist
ELANElanco Animal Health Incorporated
$24.20$12.1B
Overview & Verdict
OverviewVisualize
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice HistoryTechnical Analysis
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Ownership
Holders
HomeStocksELANBalance Sheet

Elanco Animal Health Incorporated (ELAN) Balance Sheet

10Y historyFree accessUpdated daily

Total debt has been reduced from $5.8B to $3.9B since Q1 2024, lowering D/E to 0.59, though goodwill of $4.8B (35% of assets) and negative retained earnings of -$2.1B indicate lingering acquisition-related strain.

ELAN Balance Sheet

Income StatementBalance SheetCash FlowRatios
AnnualQuarterly
MetricTTMDec'25Dec'24Dec'23Dec'22Dec'21Dec'20Dec'19Dec'18Dec'17Dec'16
Total Current Assets3.8B3.46B3.21B3.41B3.28B3.27B3.42B2.37B2.5B2.12B1.95B
Cash & Short-Term Investments530M545M468M352M345M638M495M334M474.8M323.4M258.8M
Cash Only530M545M468M352M345M638M495M334M474.8M323.4M258.8M
Short-Term Investments00000000000
Accounts Receivable1.15B940M886M1.01B1B1.03B1.08B889.9M709.4M601.9M630.7M
Days Sales Outstanding76.7372.7772.8583.4682.9178.76120.09105.7784.4376.0479.01
Inventory1.77B1.74B1.57B1.74B1.54B1.37B1.58B1.05B1B1.06B875.6M
Days Inventory Outstanding265.74237.9227.08255.46229.98186.17284.22229.55206.92226.07202.31
Other Current Assets0236M287M310M394M011M11.1M202.7M00
Total Non-Current Assets9.76B9.9B9.4B10.96B12.21B13.2B14.28B6.61B6.45B6.82B6.15B
Property, Plant & Equipment1.41B1.41B993M1.03B999M1.05B1.32B955.3M922.4M920.3M741.8M
Fixed Asset Turnover3.58x3.35x4.47x4.31x4.42x4.52x2.49x3.21x3.32x3.14x3.93x
Goodwill4.84B4.78B4.41B5.09B5.99B6.17B6.22B2.99B2.96B2.97B2.58B
Intangible Assets3.2B3.41B3.68B4.49B4.84B5.59B6.39B2.48B2.45B2.67B2.62B
Long-Term Investments0000000015.3M12.3M9M
Other Non-Current Assets304M304M311M341M378M390M348M185M103.1M242M204M
Total Assets13.56B13.36B12.61B14.36B15.49B16.48B17.69B8.99B8.96B8.94B8.1B
Asset Turnover0.37x0.35x0.35x0.31x0.28x0.29x0.19x0.34x0.34x0.32x0.36x
Asset Growth %8.77%5.9%-12.17%-7.29%-5.99%-6.87%96.9%0.32%0.18%10.38%-
Total Current Liabilities1.85B1.6B1.31B1.24B1.7B1.65B2.08B818.5M970.7M632.6M618.9M
Accounts Payable427M368M296M270M390M416M501M222.6M205.2M203.8M228.2M
Days Payables Outstanding58.2450.442.739.7558.3256.4990.2448.6342.2943.3752.73
Short-Term Debt73M74M44M38M388M294M555M24.5M29M00
Deferred Revenue (Current)00000000367.6M00
Other Current Liabilities01.16B975M933M924M937M1.02B555M736.5M169.2M307.5M
Current Ratio2.05x2.17x2.44x2.75x1.93x1.99x1.65x2.90x2.58x3.36x3.15x
Quick Ratio1.10x1.08x1.25x1.35x1.02x1.16x0.89x1.62x1.55x1.68x1.73x
Cash Conversion Cycle284.22260.27257.23299.16254.57208.44314.08286.68249.06258.75228.6
Total Non-Current Liabilities5.12B5.21B5.2B6.9B6.5B7.32B7.14B2.62B2.79B516.9M452.9M
Long-Term Debt3.85B3.94B4.28B5.74B5.45B6.03B5.57B2.33B2.44B00
Capital Lease Obligations00000000000
Deferred Tax Liabilities1.64B382M449M567M662M765M900M100.8M114.6M251.9M227.5M
Other Non-Current Liabilities551M889M477M595M390M533M668M189.1M230.6M265M225.4M
Total Liabilities6.97B6.81B6.52B8.14B8.2B8.97B9.22B3.44B3.76B1.15B1.07B
Total Debt3.92B4.02B4.32B5.77B5.84B6.32B6.13B2.35B2.47B00
Net Debt3.39B3.47B3.85B5.42B5.49B5.68B5.63B2.02B2B-323.4M-258.8M
Debt / Equity0.59x0.61x0.71x0.93x0.80x0.84x0.72x0.42x0.48x--
Debt / EBITDA3.39x4.31x4.73x5.66x5.47x6.20x13.92x3.44x4.05x--
Net Debt / EBITDA2.93x3.73x4.22x5.32x5.15x5.57x12.80x2.95x3.28x-0.70x-0.48x
Interest Coverage0.31x-0.02x2.44x-3.31x0.72x-1.16x-3.31x1.99x4.85x--
Total Equity6.59B6.55B6.1B6.22B7.29B7.51B8.48B5.55B5.2B7.79B7.03B
Equity Growth %10.42%7.4%-2.04%-14.62%-2.92%-11.42%52.81%6.72%-33.29%10.86%-
Book Value per Share13.0213.1912.2612.6414.9315.4119.2014.9816.5721.8719.73
Total Shareholders' Equity6.59B6.55B6.1B6.22B7.29B7.51B8.48B5.55B5.2B7.79B7.03B
Common Stock0000000008.05B7.48B
Retained Earnings-2.07B-2.18B-1.95B-2.29B-1.06B-979M-477M84.3M16.4M00
Treasury Stock00000000000
Accumulated OCI-219M-141M-771M-266M-392M-209M303M-173.7M-222.2M-256.6M-456.9M
Minority Interest00000000000

Key Metrics

Growth RegimeAccelerating
ProfitabilityStable
Balance SheetStrained
Cash FlowImproving
Top Statement Risk

Elevated debt and competition

Verified Source

Metrics are mathematically derived from official filings.

SEC 10-K (2026Q2)

Balance Sheet Deleveraging Trajectory

Total debt fell from $5.8B in Q1 2024 to $3.9B in Q2 2026, reducing D/E from 0.95 to 0.59, as per recent financial statements, indicating a steady deleveraging path.

The sequential decline in total debt, coupled with a stable equity base, suggests that management is prioritizing debt reduction, likely using operating cash flow. This trend is consistent with the improving cash flow signal from the income statement analysis, where FCF turned positive. However, the pace of deleveraging appears moderate, and the absolute debt level remains substantial relative to equity, warranting continued monitoring.

Leverage Eases but Remains Elevated

Debt-to-equity improved to 0.59 in Q2 2026 from 0.96 in Q2 2024, yet total debt of $3.9B still exceeds equity, as reported in SEC filings, indicating persistent leverage.

The reduction in leverage is a positive sign, but the debt load remains a constraint, especially given the negative retained earnings and the need to fund innovation. The interest burden likely continues to pressure net income, as evidenced by the negative ROE. Investors should monitor whether the company can sustain this deleveraging while also investing in growth initiatives.

Asset Mix Reflects Acquisition Legacy

Goodwill of $4.8B represents 35% of total assets in Q2 2026, per balance sheet data, highlighting the significant role of acquisitions in the company's asset base.

The large goodwill balance, stemming from the Bayer acquisition, exposes the balance sheet to potential impairment risk if growth expectations are not met. However, the recent revenue acceleration and margin expansion may mitigate that risk. The modest PPE of $1.4B suggests an asset-light manufacturing model, but the high fixed-cost base indicated in the company intelligence suggests otherwise, implying that some assets may be leased or off-balance-sheet.

Equity Quality Masked by Accumulated Deficit

Retained earnings remain deeply negative at -$2.1B in Q2 2026, as per financial statements, yet total equity of $6.6B is supported by paid-in capital, indicating a history of losses.

The negative retained earnings reflect cumulative GAAP losses, largely due to amortization and interest expenses. However, the equity base is stable, and the recent improvement in operating performance may gradually reduce the deficit. The absence of dividends and buybacks, as noted in the cash flow analysis, suggests that all earnings are being retained to support deleveraging and reinvestment.

Liquidity Buffer Remains Comfortable

Current ratio stands at 2.05 in Q2 2026, down from 3.29 in Q1 2024, but cash of $530M provides a cushion, as per recent balance sheet data, against short-term obligations.

The current ratio, while declining, remains above 2, indicating adequate short-term liquidity. However, the cash balance is relatively modest compared to total debt, and the company may need to rely on operating cash flow to meet obligations. The improving cash flow signal suggests that liquidity is not an immediate concern, but the trend in the current ratio warrants monitoring.

Goodwill Impairment Risk Looms

Goodwill of $4.8B, roughly 35% of total assets, as per balance sheet data, represents a significant impairment risk if the acquired businesses underperform, potentially distorting equity.

The large goodwill balance from the Bayer acquisition is a non-cash asset that may be subject to impairment if cash flow projections are not met. While recent performance has improved, the competitive pressures in the pet health market and the company's historical growth lag suggest that impairment testing could result in charges. Investors should monitor the company's segment performance and any indicators of impairment in future disclosures.

ELAN — Frequently Asked Questions

Quick answers to the most common questions about buying ELAN stock.

What are the total assets of Elanco Animal Health Incorporated (ELAN)?

As of 2025, Elanco Animal Health Incorporated (ELAN) had total assets of $13.36B including $3.46B in current assets.

How much debt does Elanco Animal Health Incorporated (ELAN) have?

Elanco Animal Health Incorporated (ELAN) carries total debt of $4.02B, offset by $545.0M in cash and short-term investments. Comparing total debt to cash helps evaluate the company's debt burden and net leverage.

What is the book value or shareholders' equity of Elanco Animal Health Incorporated?

Elanco Animal Health Incorporated (ELAN) has total shareholders' equity (book value) of $6.55B ($13.19 book value per share). Book value represents the net worth of the company belonging to common stock holders.

What is Elanco Animal Health Incorporated's current ratio and liquidity?

Elanco Animal Health Incorporated (ELAN) reported a current ratio of 2.17x. A current ratio above 1.0x indicates that the company has more current assets than current liabilities, suggesting sufficient short-term liquidity.